» Articles » PMID: 37582160

A Virally Encoded GPCR Drives Glioblastoma Through Feed-forward Activation of the SK1-S1P Signaling Axis

Overview
Journal Sci Signal
Date 2023 Aug 15
PMID 37582160
Authors
Affiliations
Soon will be listed here.
Abstract

The G protein-coupled receptor (GPCR) US28 encoded by the human cytomegalovirus (HCMV) is associated with accelerated progression of glioblastomas, aggressive brain tumors with a generally poor prognosis. Here, we showed that US28 increased the malignancy of U251 glioblastoma cells by enhancing signaling mediated by sphingosine-1-phosphate (S1P), a bioactive lipid that stimulates oncogenic pathways in glioblastoma. US28 expression increased the abundance of the key components of the S1P signaling axis, including an enzyme that generates S1P [sphingosine kinase 1 (SK1)], an S1P receptor [S1P receptor 1 (S1P)], and S1P itself. Enhanced S1P signaling promoted glioblastoma cell proliferation and survival by activating the kinases AKT and CHK1 and the transcriptional regulators cMYC and STAT3 and by increasing the abundance of cancerous inhibitor of PP2A (CIP2A), driving several feed-forward signaling loops. Inhibition of S1P signaling abrogated the proliferative and anti-apoptotic effects of US28. US28 also activated the S1P signaling axis in HCMV-infected cells. This study uncovers central roles for S1P and CIP2A in feed-forward signaling that contributes to the US28-mediated exacerbation of glioblastoma.

Citing Articles

Human cytomegalovirus UL82 promotes cell cycle progression of colorectal cancer by upregulating AGR2.

Ren H, Wang B, Wang L, Shi Y, Li R, Jiang C Commun Biol. 2025; 8(1):251.

PMID: 39962326 PMC: 11833063. DOI: 10.1038/s42003-025-07674-z.


G protein-coupled receptors: a gateway to targeting oncogenic EVs?.

Di Niro L, Linders A, Glynn T, Pegtel D, Siderius M, Crudden C Extracell Vesicles Circ Nucl Acids. 2024; 5(2):233-248.

PMID: 39698539 PMC: 11648488. DOI: 10.20517/evcna.2024.10.


Clinical implications of cytomegalovirus in glioblastoma progression and therapy.

Mercado N, Real J, Kaiserman J, Panagioti E, Cook C, Lawler S NPJ Precis Oncol. 2024; 8(1):213.

PMID: 39343770 PMC: 11439950. DOI: 10.1038/s41698-024-00709-4.


Sphingolipid Signaling and Complement Activation in Glioblastoma: A Promising Avenue for Therapeutic Intervention.

Janneh A Biochem (Basel). 2024; 4(2):126-143.

PMID: 38894892 PMC: 11185840. DOI: 10.3390/biochem4020007.